These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38029470)

  • 21. Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice.
    Kliwinski C; Cooper PR; Perkinson R; Mabus JR; Tam SH; Wilkinson TM; Giles-Komar J; Scallon B; Powers GD; Hornby PJ
    Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(3):G262-70. PubMed ID: 23220220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn).
    Ferl GZ; Wu AM; DiStefano JJ
    Ann Biomed Eng; 2005 Nov; 33(11):1640-52. PubMed ID: 16341929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
    Cao Y; Balthasar JP; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):597-607. PubMed ID: 23996115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system.
    Chang HY; Wu S; Chowdhury EA; Shah DK
    J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):337-362. PubMed ID: 35092540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies.
    Roopenian DC; Christianson GJ; Proetzel G; Sproule TJ
    Methods Mol Biol; 2016; 1438():103-14. PubMed ID: 27150086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
    Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
    MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.
    Avery LB; Wang M; Kavosi MS; Joyce A; Kurz JC; Fan YY; Dowty ME; Zhang M; Zhang Y; Cheng A; Hua F; Jones HM; Neubert H; Polzer RJ; O'Hara DM
    MAbs; 2016; 8(6):1064-78. PubMed ID: 27232760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.
    Niederalt C; Kuepfer L; Solodenko J; Eissing T; Siegmund HU; Block M; Willmann S; Lippert J
    J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):235-257. PubMed ID: 29234936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.
    Haraya K; Tachibana T; Nanami M; Ishigai M
    Xenobiotica; 2014 Dec; 44(12):1127-34. PubMed ID: 25030041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy?
    Bequignon E; Dhommée C; Angely C; Thomas L; Bottier M; Escudier E; Isabey D; Coste A; Louis B; Papon JF; Gouilleux-Gruart V
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30893823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
    Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
    MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
    Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
    Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of Human Pharmacokinetics Profile of Monoclonal Antibody Using hFcRn Transgenic Mouse Model.
    Nakamura G; Ozeki K; Takesue H; Tabo M; Hosoya KI
    Biol Pharm Bull; 2021; 44(3):389-395. PubMed ID: 33642546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Physiologically-Based Pharmacokinetic Model for the Prediction of "Half-Life Extension" and "Catch and Release" Monoclonal Antibody Pharmacokinetics.
    Jones HM; Tolsma J; Zhang Z; Jasper P; Luo H; Weber GL; Wright K; Bard J; Bell R; Messing D; Kelleher K; Piche-Nicholas N; Webster R
    CPT Pharmacometrics Syst Pharmacol; 2020 Sep; 9(9):534-541. PubMed ID: 32697437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of Neonatal Fc Receptor and Beta-2 Microglobulin in Human Liver Tissues by Ultraperformance Liquid Chromatography-Multiple Reaction Monitoring-based Targeted Quantitative Proteomics for Applications in Biotherapeutic Physiologically-based Pharmacokinetic Models.
    Qiu X; Wang MZ
    Drug Metab Dispos; 2020 Oct; 48(10):925-933. PubMed ID: 32723849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
    Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
    MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats.
    Sepp A; Meno-Tetang G; Weber A; Sanderson A; Schon O; Berges A
    J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):339-359. PubMed ID: 31079322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neonatal Fc receptor FcRn is involved in intracellular transport of the Fc fusion protein aflibercept and its transition through retinal endothelial cells.
    Deissler HL; Lang GK; Lang GE
    Exp Eye Res; 2017 Jan; 154():39-46. PubMed ID: 27836572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody.
    Urva SR; Yang VC; Balthasar JP
    J Pharm Sci; 2010 Mar; 99(3):1582-600. PubMed ID: 19774657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.